Cognex Corp SEC Filings

Cognex Corporation reported stronger operations in Q3 2025, with revenue of $276,892,000, up 18% year over year, and gross margin steady at 68%. Operating income rose to $57,765,000 (21% of revenue) as expenses were essentially flat, reflecting cost controls and higher incentive accruals tied to performance.

Net income fell to $17,664,000, or $0.10 per diluted share, primarily due to a discrete tax expense of approximately $33,265,000 from newly enacted U.S. tax legislation (OBBBA), which lifted the effective tax rate to 72%. Excluding discrete items, the company cited an effective tax rate of 18% for the quarter.

Geographically, revenue grew in the Americas (+27%) and Europe (+30%), with Greater China up 10% and Other Asia down 4%. Results included about $13 million of one-time license and inventory transfer revenue from a new medical lab automation partnership. Year to date, operating cash flow was $170,612,000; cash and investments totaled $600,344,000. The company repurchased 3,594,000 shares for $126,233,000, leaving $140,020,000 authorized, and declared a subsequent dividend of $0.085 per share.

Cognex Corporation reported two updates. The company furnished a news release with financial results for the quarter ended September 28, 2025 as Exhibit 99.1. In addition, the Board of Directors declared a quarterly cash dividend of $0.085 per share, payable on November 28, 2025 to shareholders of record at the close of business on November 13, 2025.

The earnings release was provided as an exhibit and designated as furnished, not filed, under the Exchange Act. Cognex’s common stock trades on NASDAQ under the symbol CGNX.

Cognex (CGNX) director Robert Willett reported an option exercise and same‑day sale. On 10/21/2025, he exercised 6,704 non-qualified stock options at an exercise price of $38.39 per share and sold 6,704 common shares at an average price of $49.5062. The transactions were effected pursuant to a Rule 10b5‑1 trading plan.

Following these transactions, the filing shows 0 shares held directly and 15,804 shares held indirectly by a trust. The report also lists multiple outstanding option grants and a restricted stock unit award, reflecting ongoing equity incentives with stated vesting and expiration dates.

Sheila Marie DiPalma, Executive Vice President, Employee Services at Cognex Corporation (CGNX), reported open-market dispositions under a Rule 10b5-1 trading plan. On 09/05/2025 she sold 2,002 shares at $45.00, reducing her direct common stock holding to 8,582 shares. On 09/08/2025 she sold 2,000 shares at $45.03, reducing holdings to 6,582 shares. The filing lists substantial outstanding option and restricted stock unit positions exercisable into common stock, totaling tens of thousands of shares across multiple option grants and RSU awards.

Laura A. MacDonald, Vice President and Principal Accounting Officer of Cognex Corporation (CGNX), reported transactions on Form 4 showing an open-market sale and her remaining holdings. On 09/05/2025 she sold 2,666 shares of Cognex common stock at $45 per share pursuant to a Rule 10b5-1 trading plan. After that sale she directly owned 4,593 shares. She also reports 20 shares held by her child, which she disclaims beneficial ownership of except for pecuniary interest.

The filing lists detailed equity compensation holdings: multiple outstanding non-qualified stock options totaling 238,695 underlying shares and restricted stock units totaling 33,914 shares (by schedule), with various exercise prices and expiration dates.

Form 144 notice for Cognex Corp (CGNX): This filing notifies the proposed sale of 4,002 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $177,168.54. The shares represent restricted stock units acquired from the issuer on 02/22/2023 and the filer lists the approximate date of sale as 09/05/2025 on the NASDAQ. The filing reports no securities sold in the past three months for the account and includes the standard signature representation that the seller is not aware of undisclosed material adverse information.

Form 144 notice for Cognex Corp (CGNX) reports a proposed sale of 2,666 shares of Common Stock through broker Robert W Baird & Co., with an aggregate market value of $119,970 and approximate sale date of 09/05/2025 on NASDAQ. The filing shows the 2,666 shares were acquired through three Restricted Stock Unit releases on 02/21/2025, 02/22/2025 and 03/15/2025 totaling 2,666 shares, and fully settled upon vesting. The filing states there were no securities sold in the past three months by the reporting person. Filer contact and issuer identification fields in the notice are present but contain no specific names or CIK values in the provided content.

Matthew Moschner, CEO & President and a director of Cognex Corporation (CGNX), reported equity activity tied to restricted stock units that vested on 08/07/2025. A grant of 3,000 restricted stock units vested on that date, and 881 shares were withheld to satisfy tax-withholding obligations at a reported price of $41.36 per share. The Form 4 shows each RSU converts to one share and explains the vesting schedule for the grant (approximately 20%, 30% and 50% on the first three anniversaries of the grant date). The filing also details the reporting person’s outstanding stock option positions and other RSU balances, including a large option block of 279,070 options at a $27.99 strike, documenting the executive’s continuing equity holdings in the company.